EXOME

all the information, none of the junk | biotech • healthcare • life sciences

Bydureon FDA Deadline Set

Xconomy San Diego — 

San Diego-based Amylin Pharmaceuticals (NASDAQ: AMLN), Indianapolis-based Eli Lilly (NYSE: LLY), and Waltham, MA-based Alkermes (NASDAQ: ALKS) said today that the FDA has set a deadline of Jan. 28 to complete its review of the newly updated application for exenatide once-weekly (Bydureon). The companies are seeking FDA clearance to start marketing the new product as the first once-weekly injectable medicine for diabetes patients in the U.S. The drug was approved in the European Union in June.